AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

A month has gone by since the last earnings report for Euronet Worldwide (EEFT). Shares have lost about 2.9% in that time frame, outperforming the S&P 500. Will the recent negative trend continue ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

The University of Michigan's closely watched index of consumer sentiment declined sharply to 57.9 in mid-March from 64.7 last month. It marks the lowest level since 2022. Gold has exceeded $3,000 a ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Former CDC nominee goes scorched earth, blaming two Republicans and ‘big Pharma’ for failed bid - Weldon’s nomination to head the CDC was withdrawn just 12 hours before he was supposed to testify to t ...

The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...

The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...